Alvise Mattana

512P Molecular landscape of BRCA-mutated NSCLC

Daniele Lorenzini, Adele Busico, Francesca Barbetta, M. De Ponti et autres

Next-generation sequencing (NGS) has become increasingly widespread in non-small cell lung cancer (NSCLC); although rare, BRCA1/2 mutations (mBRCA) have been reported. Whether these cases represent a distinct subgroup remains a matter of debate.

it (code pays fourni par la source)

International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)

Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti et autres

BACKGROUND: Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI monotherapy …

it, us, gb (code pays fourni par la source)

Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study

Veronica Mollica, Francesco Massari, Marco Maruzzo, Davide Bimbatti et autres

it (code pays fourni par la source)

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors

Brigida Anna Maiorano, Massimo Di Maïo, Linda Cerbone, Evaristo Maiello et autres

Importance: Immune checkpoint inhibitors (ICIs) have broadened the metastatic urothelial carcinoma (mUC) therapeutic scenario. The association of programmed death ligand 1 (PD-L1) with response and survival in patients treated with ICIs is still controversial. Objectives: To evaluate the association of PD-L1 with …

it (code pays fourni par la source)

International multicenter real-world registry for patients with metastatic renal cell carcinoma: Meet-URO 33 study (REGAL study).

Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti et autres

TPS485 Background: Nowadays, different systemic treatments are available for the first-line setting of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless the IMDC risk category, even though TKI monotherapy is still a therapeutic option …

it, gb (code pays fourni par la source)

International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma – Meet-URO 33 study (REGAL study)

Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti et autres

Abstract Background: Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the International Metastatic RCC Database Consortium (IMDC) risk category, even though TKI …

it, gb (code pays fourni par la source)

Tossicologia di genere in oncologia - un breve excursus

Alvise Mattana, Eleonora Lai, Umberto Basso, Davide Bimbatti et autres

L'Organizzazione Mondiale della Sanità (OMS) definisce il termine "genere" come il risultato di criteri costruiti su parametri sociali e su ruoli attribuiti ad un sesso e come elemento portante per la promozione della salute.[1] In ambito medico il concetto di genere viene …

it (code pays fourni par la source)

The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma

Francesco Pierantoni, Michele Dionese, Umberto Basso, Eleonora Lai et autres

INTRODUCTION: A low fT3/fT4 ratio has been associated with a poorer prognosis in patients treated for different solid malignancies. However, the prognostic role of baseline thyroid function in patients with metastatic urothelial carcinoma (mUC) has not yet been established. PATIENTS AND METHODS: …

it (code pays fourni par la source)

Multi-institutional prostate cancer unit of Padova: Review of activity and performance indicators of the first 18 months after ISO9001 certification.

Marco Maruzzo, Umberto Basso, Eugenio Miglioranza, Paolo Corsi et autres

337 Background: The development of Prostate Cancer Units (PCUs) determined a paradigm shift in the treatment of this disease based on multidisciplinary management and shared clinical pathways among several specialists, but activities of PCUs are rarely reported. The Multi-Institutional PCU of Padova …

it (code pays fourni par la source)

Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9.

Alvise Mattana, Marzia Del Re, Davide Bimbatti, Sebastiano Buti et autres

648 Background: The oral tyrosine kinase inhibitor Cabozantinib (CABO) is frequently used to treat patients with metastatic RCC. Polypharmacy is common in elderly pts, thus several drug-drug interactions (DDIs) with cabozantinib may ensue. Methods: ZEBRA /MEET-URO 9 was a prospective, real world …

it (code pays fourni par la source)

Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9).

Umberto Basso, Sebastiano Buti, Elena Verzoni, Mariella Sorarù et autres

647 Background: Cabozantinib (CABO) is an oral tyrosine kinase inhibitor registered for the treatment of metastatic renal cell carcinoma (mRCC) for the first or subsequent lines. Tolerability in real world elderly patients is poorly documented. G8 is a short test for vulnerability …

it (code pays fourni par la source)

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience

Davide Bimbatti, Michele Dionese, Eleonora Lai, Nicolò Cavasin et autres

Introduction: Immunotherapy with nivolumab (a monoclonal antibody that targets the programmed cell death protein 1, PD1) has become the standard treatment for patients with metastatic renal cell carcinoma (mRCC) after progression to single-agent tyrosine kinase inhibitors. However, the optimal duration of immunotherapy …

it (code pays fourni par la source)